Although evidence of a causative link between hyperuricemia and cardiometabolic risk is mounting, it still does not support the use of pharmacotherapy and its concentration is not used in equations for estimating vascular risk. Asymptomatic hyperuricemia is a frequent, coincidental, biochemical finding that does not require any treatment.
Uric acid should not be measured routinely, but its measurement may be considered mainly in the following situations:
-Investigation of acute joint pain -Follow-up of hypouricemic treatment -Follow-up of patients with kidney disease and kidney stone disease -Preeclampsia -Tumor lysis syndrome
For more information:
James W Lohr et al. Hyperuricemia treatment and management. August 2018. [Internet].
Khanna D, et al. American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. PMID: 23024028.
Paul BJ et al. Asymptomatic hyperuricemia: is it time to intervene? Clinical Rheumatology. 2017 Dec;36(12):2637-2644. PMID: 28980141.
Stamp L, Dalbeth N. Urate lowering therapy for asymptomatic hyperuricemia. A need for caution. Semin Arthritis Rheum. 2017 Feb;46(4):457-464. PMID: 27591828.